Retatrutide-Peptide.biz
Cart (0)
98%+ purity, third-party verified◆Ships from the USA in 1–2 business days◆Free shipping over $200◆Research use only

Resources

Primary sources

All of our references are compiled in one place. Scholarly articles appear first, then clinical trial registries, and after that corporate and official organization pages. We leave out blogs, forums, and vendor sites.

Peer-reviewed publications

Jastreboff et al., NEJM 2023Phase 2, obesity, 48-week results Rosenstock et al., Lancet 2023Phase 2, type 2 diabetes, 36-week results Sanyal et al., Nature Medicine 2024Phase 2 substudy, liver fat

Trial registries

NCT05929066, TRIUMPH-1Phase 3, obesity / overweight NCT05929079, TRIUMPH-2Phase 3, obesity with type 2 diabetes NCT06383390Phase 3, TRIUMPH program

Company announcements

Eli Lilly, Phase 2 announcement2023 Eli Lilly, TRIUMPH-2 and -3 toplineJuly 2026, BLA planned Q1 2027

Regulators and public health

FDA MedWatchAdverse event reporting FDA, compounding lawsSections 503A / 503B NIDDKBackground on obesity medications

Outbound links take you to third-party sites we do not control. Their inclusion does not signal approval, and those organizations are not affiliated with our store.